"IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ"

Study acronym: ILIPO
StatusRecruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Nov 1, 2028 → Apr 7, 2029
See other at-risk trials from Nantes University Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 7 more changesShow less
    • Start date changed from estimate of May 1, 2026 to Oct 7, 2026
    • Primary completion pushed from Nov 1, 2028 to Apr 7, 2029
    • Study completion moved earlier from Nov 1, 2029 to Apr 7, 2029
    • Study sites: 1 to 2
    • Interventions: Anakinra 100Mg/0.67Ml Inj Syringe (Drug) to Anakinra 100Mg/0.67Ml Inj Syringe (Drug)
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 11 of 17 entries
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
A prospective, open-label, uncontrolled, non-randomized, single-center Phase I/II clinical trial evaluating the safety of Anakinra in the immediate post-transplant period following pancreatic transplantation
Trial Details
NCT Number NCT07503834
Lead Sponsor Nantes University Hospital
Conditions
(from sponsor)		 Pancreatic Transplant
Related terms Thromboinflammation
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov